TX-200

N/A

Report date: 2023/02/07 14:41:33

Base Information

Drug NameTX-200
Drug Alias NameAutologous naive regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor to recognise the HLA-A*02 antigenHLA-A2-specific CAR-Treg cell therapy (TxCell)Autologous naive regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor to recognise the HLA-A*02 antigen (TxCell)ENTX-SOTHLA-A2 CAR-Treg-TxCell +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > CAR-Tregs +[4] 
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-HLA-A2
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsRejection of renal transplantationKidney Failure, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics IncThe University Of British Columbia
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationKidney Failure, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A